No Data
No Data
Afternoon session [Active stocks and traded stocks]
*Drecom <3793> 1036 +50 The location-based gaming "Disney STEP" by Disney will start service on March 3. *Tama-Irazu <2477> 3170 +120 Announced a share buyback with a limit of 4.0% of the outstanding shares. *Pia <4337> 2990 -180 Announced a stock offering. *Starzen <8043> 2801 -88 Announced a stock offering, share buyback, and stock splits. *PXB <6190> 611 +100 with TOPPANHD.
Stocks that hit the upper or lower limit in the afternoon session.
■ Limit Up <3195> Generation Pass <4673> Kawasaki Geoscience <6171> Civil Engineering Management Comprehensive Testing Institute <6190> Phoenix Bio <6835> Allied Teleisys Holdings <7091> Living Platform <8783> GFA <9229> Sunwells ■ Limit Down <3905> Data Section *Includes temporary limit up and down (quoted prices).
PXB has signed a business partnership agreement with TOPPAN for the trial supply of "artificial three-dimensional liver tissue."
PhoenixBio (PXB) announced on the 19th that it has signed a business partnership agreement with Toppan Holdings (7911.T) to provide samples of "artificial three-dimensional liver tissue" produced in vitro using Toppan's developed 3D cell culture technology "in vivoid." With this partnership, the company's fresh human liver cells "PXB-cells" will be combined with Toppan's "in vivoid" to create the "artificial three-dimensional liver tissue" (liver).
Due to a decline in research and development activities by overseas pharmaceutical companies, PXB---3Q experienced a reduction in revenue.
Phoenix Bio Co., Ltd. (6190) announced its consolidated financial results for the third quarter of the fiscal year ending March 2025 (April-December 2024) on the 14th. Revenue was 1.143 billion yen, a decrease of 13.9% compared to the same period last year, with an operating loss of 0.153 billion yen (compared to a profit of 0.03 billion yen in the same period last year), an ordinary loss of 0.146 billion yen (compared to a profit of 0.032 billion yen in the same period last year), and a quarterly net loss attributable to shareholders of the parent company of 0.15 billion yen (compared to a profit of 0.014 billion yen in the same period last year). The demand for PXB mice has shifted from the hepatitis field to the biopharmaceutical field.
PhoenixBio: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Inter-trade etc [Stocks with notable appeal viewed from volume change]
Closing prices and volume compared to the previous day *<6190> PXB 3646447100 *<5616> Rain, Wind, Sun 84912672300 *<3747> Intertrade 441694784100 *<4406> Shin Nihon Rika 212221919600 *<7162> Astomax 2595499600 *<4772> Stream M 131142906000 *<7578> Nichiryouku 1508124900 *<4331> T & G Needs 87479221600 *<41